Tag Archives: R&D

Pharma in Argentina: An Interview with Juan Pablo Bagó

2014 marked the 80th anniversary of Laboratorios Bagó, a market leader in Argentina and also  Latin America, with products in  in 47 countries. In this interview with Pharmaboardroom.com, Juan Pablo Bagó, general director of pharma in Argentina for the Bagó group, discusses the state of R&D in Argentina, and explains why his group is planning for a 75 percent of turnover […]
Posted in Emerging Markets, Global, R&D, Strategy | Also tagged , , , | Leave a comment

Cancer Medicines: Setbacks and Stepping Stones

A report released on this week by the Pharmaceutical Research and Manufacturers of America (PhRMA), “Researching Cancer Medicines: Setbacks and Stepping Stones,” highlights the number of investigational cancer medicines that did not succeed in clinical trials and how these so-called “failures” are a crucial part of the drug development process.
Posted in healthcare, R&D | Also tagged , , , | 1 Comment

The Future of Oncology is Now

Applied Clinical Trials’ Lisa Henderson speaks to Novella Clinical CEO Richard Staub. Last August, Quintiles announced its intention to purchase Novella Clinical, specifically for its focus on small and mid-sized oncology biopharma clients, as well as medical device and diagnostics companies. We checked in with Novella President Richard Staub to discuss post-acquisition life, outsourcing, and […]
Posted in R&D | Also tagged , , | Leave a comment

Big Data in the Pharma R&D Landscape

Big Data and the mindset that comes with it will have a fundamental impact on how pharmaceutical research will be conducted in the future, writes Peter Tormay. Innovation is the corner stone of the pharmaceutical industry. Unfortunately, the industry as a whole is not very good at it. For the last two decades the approval […]
Posted in Guest Blog, R&D, Strategy, Technology | Also tagged , | Leave a comment

Rebranding Risk-Based Monitoring in Clinical R&D

With all of the buzz and excitement around risk-based monitoring (RBM), one might expect that the broad adoption of this emerging clinical research paradigm is well underway. Those familiar with the often painfully slow pace of innovation in the area of clinical R&D, however, will not be surprised by the more sobering reality that only […]
Posted in R&D | Also tagged , | Leave a comment
  • Categories

  • Meta